A non-Newtonian, lyophilic colloid comprised of (i) at least one anionic, non-sulfated glycosaminoglycan (ANSG) having a molecular weight greater than about 500 kDa and (ii) glycerin.

A non-Newtonian, lyophilic colloid comprised of (i) at least one anionic, non-sulfated glycosaminoglycan (ANSG) having a molecular weight greater than about 500 kDa and (ii) glycerin.

The invention provides probiotic bacteria and lysates thereof for use in methods of medical and cosmetic treatment. Use in the treatment of infections, including skin infections and methods involving regeneration or repair of the skin barrier are contemplated.

The invention provides probiotic bacteria and lysates thereof for use in methods of medical and cosmetic treatment. Use in the treatment of infections, including skin infections and methods involving regeneration or repair of the skin barrier are contemplated.

The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.

The present invention relates to a composition comprising probiotics, preferably based on bacteria, in particular of the genus Lactobacillus, to be used for the purpose of preventing and/or treating the disorders affecting the skin, in particular inflammatory disorders, in particular autoinflammatory disorders of dermatological interest such as atopic dermatitis. Furthermore, the composition of the invention is useful for preventing and/or reducing the damage induced by UV radiation, in particular skin aging.

The present disclosure provides an admixture of Staphylococcus (S.) epidermidis cells selected from S. epidermidis Type I cells, S. epidermidis Type II cells, S. epidermidis Type III cells, S. epidermidis Type Mvb cells, and S. epidermidis Type IV cells capable of modified expression of virulence factor genes and other genes that contribute to virulence, such as nitrogen respiration genes, ureases activity genes, carbohydrate metabolism genes, iron uptake genes, sulfur metabolism genes. The present disclosure also provides methods of treating or preventing skin disease and reducing the risk of recurrent skin disease in a subject by administering the admixtures of S. epidermidis cell types.

The present disclosure is directed to a composition for managing exaggerated sebum production in oily-prone skin, the composition containing: (1) a mixture of at least: (a) from about 0.02 to about 1% by weight of an ingredient capable of activating cannabinoid type-2 receptors (“CB.sub.2”); (b) from about 0.1 to about 3% by weight of a blend of Tetraselmis chuii and Fucus spiralis algae extracts; (c) from about 0.1 to about 4% by weight of an extract of Centella asiatica; and (d) from about 0.01 to about 0.05% by weight of an extract of Tulsi, wherein all weights are based on total weight of the composition; (2) optionally, an emulsifier; and (3) a dermatologically acceptable carrier, wherein the composition has a pH ranging from about 4.5 to about 5.5.

The present disclosure is directed to a composition for managing exaggerated sebum production in oily-prone skin, the composition containing: (1) a mixture of at least: (a) from about 0.02 to about 1% by weight of an ingredient capable of activating cannabinoid type-2 receptors (“CB.sub.2”); (b) from about 0.1 to about 3% by weight of a blend of Tetraselmis chuii and Fucus spiralis algae extracts; (c) from about 0.1 to about 4% by weight of an extract of Centella asiatica; and (d) from about 0.01 to about 0.05% by weight of an extract of Tulsi, wherein all weights are based on total weight of the composition; (2) optionally, an emulsifier; and (3) a dermatologically acceptable carrier, wherein the composition has a pH ranging from about 4.5 to about 5.5.

Ammonia oxidizing microorganism preparations for delivery to the visual and auditory systems, kits including ammonia oxidizing preparations for delivery to the visual and auditory systems, and devices for administering ammonia oxidizing preparations to the visual and auditory systems are provided. Methods of introducing ammonia oxidizing microorganisms to the eye are provided. Methods of introducing ammonia oxidizing microorganisms to the ear are provided. Methods of treating disorders, including eye disorders, ear disorders, and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.